好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

An Instrumented Timed Up and Go is Sensitive to Progression in Facioscapulohumeral Dystrophy
Neuromuscular and Clinical Neurophysiology (EMG)
S23 - Genetic Muscle Disorders (4:14 PM-4:25 PM)
005
FSHD is characterized by variability between individuals, asymmetry of muscle involvement, and slow progression.  TFTs are not sensitive to progression over timeframes typical for clinical trials (6 months – 1 year).

Here we determine if instrumenting timed functional tasks (TFTs) with wireless inertial motion sensors improves sensitivity to disease progression and movement pattern changes in facioscapulohumeral muscular dystrophy (FSHD).

We performed a longitudinal study in 10 genetically confirmed, clinically affected individuals at the University of Kansas Medical Center.  At each visit an instrumented timed up and go (iTUG) was performed with participants wearing 6 wireless inertial sensors (OPAL, APDM, Portland, OR).  We determined the average monthly slope of progression and estimated 12-month change for temporal and spatial motion parameters and compared to the TFT duration. We created a summary iTUG Z-score made up of stride velocity and trunk sagittal range of motion.

Participants were followed on average for 20.6 months, were middle aged and spanned a full range of ambulatory severities.  The average iTUG duration stayed constant; whereas stride length, stride velocity, and trunk sagittal range of motion changed indicating poorer performance over time.  Arm swing changed in a compensatory direction towards the normative means.  The iTUG Z score declined an estimated 48% at one year (95% confidence limit -75, -18) indicating poorer performance over time.

The iTUG motion parameters were more sensitive to FSHD progression than the traditional TFT which supports the iTUG approach for future FSHD clinical trials or other muscular dystrophies.

Authors/Disclosures
Jeffrey Statland, MD (University of Kansas Medical Center)
PRESENTER
Dr. Statland has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arrowhead. Dr. Statland has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ML Bio. Dr. Statland has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Epic Bio. Dr. Statland has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Armatus . Dr. Statland has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kate Therapeutics. Dr. Statland has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Vita Therapeutics. Dr. Statland has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Dyne Therapeutics. Dr. Statland has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Avidity . Dr. Statland has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Fulcrum Therapeutics. Dr. Statland has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Statland has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Vertex . The institution of Dr. Statland has received research support from NIH. The institution of Dr. Statland has received research support from FSHD Society. The institution of Dr. Statland has received research support from Friends of FSH Research. The institution of Dr. Statland has received research support from FSHD Canada. The institution of Dr. Statland has received research support from MDA.
No disclosure on file
Jessie Huisinga No disclosure on file